Month: July 2023

July 4, 2023 Vantiva: Information concerning the total number of voting rights and shares, provided pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés FinanciersVantiva Shares(ISIN Code FR0013505062)Date Number of Outstanding Shares Number of Voting RightsJune 30, 2023   355,419,480     Number of Theoretical Voting Rights(1): 355,419,480    Number of Voting Rights Exercisable at Shareholders’ meeting(2): 355,419,480  (1)    Calculated, pursuant to Article 223-11 of the General Regulations of the Autorité des Marchés Financiers, based on the total number of outstanding shares to which voting rights are attached, including shares with suspended voting rights. (2)    Excluding shares with suspended voting rights. *                ** About Vantiva www.vantiva.com...

Company successfully executes international sale and fulfilment of 100kg order of Bulk Medical Cannabis with Lyphe Australia Company also issues Deferred Share Units to Board of Directors as Quarterly Director’s RemunerationTORONTO, July 04, 2023 (GLOBE NEWSWIRE) — Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE: 4WE) (“Entourage” or the “Company“), a Canadian producer and distributor of award-winning cannabis products, announced today the successful sale, execution and fulfilment of its first international order of 100kg of bulk medical cannabis to Australia. The Company expands its medical portfolio in partnership with Lyphe Australia Pty Ltd. (“Lyphe”), a wholly-owned subsidiary of Lyphe Group Ltd., which specializes in medical cannabis access for patients. Lyphe will now offer four of the...

PharmAla’s Australian Joint Venture Orders First Shipment of MDMA and Psilocybin for Commercial Use VANCOUVER, British Columbia, July 04, 2023 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that Cortexa, its Joint Venture with Australian company Vitura Health (ASX:VIT) has executed its first purchase order for PharmAla’s GMP LaNeo MDMA, in both finished capsule and raw API forms. Cortexa will also be ordering an amount of GMP Psilocybin API. “The long-term view on Cortexa is that it must – and will – stand on its own two feet in the Australian market, which we believe is more than capable of supporting manufacturing operations...

TORONTO, July 04, 2023 (GLOBE NEWSWIRE) — Northfield Capital Corporation (“Northfield”) (TSX-V: NFDA) is pleased to announce that it has participated in the first tranche of a private placement of units (the “Offering”) of Hemlo Explorers Inc. (“Hemlo”) which closed today. Northfield is an insider of Hemlo as it holds greater than 10% of the issued and outstanding common shares of Hemlo. In connection with the Offering, Northfield invested an aggregate amount of $200,000.03 in cash and acquired a total of 2,666,667 common shares and warrants exercisable into 2,666,667 common shares. The participation by Northfield in the Offering was considered a “related party transaction” under the policies of the TSX Venture Exchange (the “TSXV”) and for the purposes of Multilateral Instrument 61-101 – Protection of Minority Security Holders...

VANCOUVER, British Columbia, July 04, 2023 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), an innovative health services company transforming the delivery of care, today announced that it has closed the sale of its U.S. based Electronic Medical Records (“EMR”), Practice Management (“PM”), and Revenue Cycle Management (“RCM”) assets for approximately US$6.3 million. The sale was pursuant to a definitive agreement (the “Agreement”) with a subsidiary of N. Harris Computer Corporation (“Harris”) and follows the sale of CloudMD’s Canadian EMR business in October 2022. Karen Adams, CEO of CloudMD, commented, “We continue to successfully execute our strategy of focusing on our higher growth and margin businesses while surfacing value from non-core assets...